Molecular Templates Inc
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for th… Read more
Molecular Templates Inc (MTEM) - Net Assets
Latest net assets as of June 2024: $7.11 Million USD
Based on the latest financial reports, Molecular Templates Inc (MTEM) has net assets worth $7.11 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.70 Million) and total liabilities ($19.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.11 Million |
| % of Total Assets | 26.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -95.91% |
| 10-Year Change | N/A |
| Growth Volatility | 138.16 |
Molecular Templates Inc - Net Assets Trend (2002–2023)
This chart illustrates how Molecular Templates Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Molecular Templates Inc (2002–2023)
The table below shows the annual net assets of Molecular Templates Inc from 2002 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $4.21 Million | +127.84% |
| 2022-12-31 | $-15.13 Million | -123.05% |
| 2021-12-31 | $65.66 Million | +10.65% |
| 2020-12-31 | $59.34 Million | -42.40% |
| 2019-12-31 | $103.03 Million | +2.10% |
| 2018-12-31 | $100.91 Million | +30.56% |
| 2017-12-31 | $77.29 Million | +288.62% |
| 2016-12-31 | $19.89 Million | -51.31% |
| 2015-12-31 | $40.85 Million | +270.36% |
| 2014-12-31 | $-23.98 Million | -2.13% |
| 2013-12-31 | $-23.48 Million | -69.46% |
| 2012-12-31 | $-13.85 Million | -409.01% |
| 2011-12-31 | $4.48 Million | -9.31% |
| 2010-12-31 | $4.94 Million | -78.18% |
| 2009-12-31 | $22.66 Million | +5.80% |
| 2008-12-31 | $21.41 Million | +9.33% |
| 2007-12-31 | $19.59 Million | -55.72% |
| 2006-12-31 | $44.24 Million | -50.50% |
| 2005-12-31 | $89.37 Million | +437.58% |
| 2004-12-31 | $-26.47 Million | -173.06% |
| 2003-12-31 | $-9.70 Million | -263.52% |
| 2002-12-31 | $-2.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Molecular Templates Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45019800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.12% |
| Other Components | $457.10 Million | 10852.30% |
| Total Equity | $4.21 Million | 100.00% |
Molecular Templates Inc Competitors by Market Cap
The table below lists competitors of Molecular Templates Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
One2tribe S.A.
WAR:O2T
|
$566.95 |
|
Aperture Health Inc
PINK:ELNX
|
$567.29 |
|
Bluefire
PINK:BLFR
|
$567.72 |
|
OLYMPIA CAPITAL HOLDINGS LTD
XNAI:OCH
|
$568.31 |
|
Enka de Colombia S.A.: ENKA
CM:ENKA
|
$565.94 |
|
Alfalah Consumer
KAR:ACIETF
|
$565.28 |
|
KTL GLOBAL
BE:5K1
|
$565.20 |
|
Autins Group plc
LSE:AUTG
|
$564.69 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecular Templates Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -15,132,000 to 4,212,000, a change of 19,344,000.
- Net loss of 8,124,000 reduced equity.
- New share issuances of 18,383,000 increased equity.
- Other comprehensive income increased equity by 66,000.
- Other factors increased equity by 9,019,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.12 Million | -192.88% |
| Share Issuances | $18.38 Million | +436.44% |
| Other Comprehensive Income | $66.00K | +1.57% |
| Other Changes | $9.02 Million | +214.13% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Molecular Templates Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $-6.02 | $0.00 | x |
| 2003-12-31 | $-21.87 | $0.00 | x |
| 2004-12-31 | $-22530.21 | $0.00 | x |
| 2005-12-31 | $3256.02 | $0.00 | x |
| 2006-12-31 | $1205.29 | $0.00 | x |
| 2007-12-31 | $523.27 | $0.00 | x |
| 2008-12-31 | $380.95 | $0.00 | x |
| 2009-12-31 | $190.79 | $0.00 | x |
| 2010-12-31 | $24.23 | $0.00 | x |
| 2011-12-31 | $16.12 | $0.00 | x |
| 2012-12-31 | $-42.16 | $0.00 | x |
| 2013-12-31 | $-66.98 | $0.00 | x |
| 2014-12-31 | $-62.41 | $0.00 | x |
| 2015-12-31 | $91.72 | $0.00 | x |
| 2016-12-31 | $45.88 | $0.00 | x |
| 2017-12-31 | $101.69 | $0.00 | x |
| 2018-12-31 | $51.13 | $0.00 | x |
| 2019-12-31 | $40.92 | $0.00 | x |
| 2020-12-31 | $18.70 | $0.00 | x |
| 2021-12-31 | $17.81 | $0.00 | x |
| 2022-12-31 | $-4.03 | $0.00 | x |
| 2023-12-31 | $0.94 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecular Templates Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.18%
- • Asset Turnover: 1.62x
- • Equity Multiplier: 8.40x
- Recent ROE (-192.88%) is below the historical average (-79.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.19 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.33 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.92 Million |
| 2005 | -49.69% | -6435.94% | 0.01x | 1.14x | $-53.34 Million |
| 2006 | -125.88% | -3811.50% | 0.03x | 1.29x | $-60.11 Million |
| 2007 | -156.55% | -2135.38% | 0.06x | 1.32x | $-32.62 Million |
| 2008 | -85.42% | -1270.28% | 0.06x | 1.15x | $-20.43 Million |
| 2009 | -104.37% | -1642.22% | 0.03x | 2.15x | $-25.91 Million |
| 2010 | -377.95% | 0.00% | 0.00x | 3.28x | $-19.18 Million |
| 2011 | -572.23% | -41375.81% | 0.00x | 5.00x | $-26.10 Million |
| 2012 | 0.00% | -1212.46% | 0.07x | 0.00x | $-69.75 Million |
| 2013 | 0.00% | -227.41% | 0.12x | 0.00x | $-26.07 Million |
| 2014 | 0.00% | -146.61% | 0.22x | 0.00x | $-19.19 Million |
| 2015 | 107.29% | 56.97% | 1.43x | 1.31x | $39.74 Million |
| 2016 | -121.15% | 0.00% | 0.00x | 1.22x | $-26.08 Million |
| 2017 | -29.94% | -960.96% | 0.03x | 1.17x | $-30.87 Million |
| 2018 | -30.02% | -415.86% | 0.05x | 1.39x | $-40.38 Million |
| 2019 | -67.49% | -356.62% | 0.11x | 1.69x | $-79.84 Million |
| 2020 | 176.80% | 556.73% | 0.13x | 2.36x | $98.98 Million |
| 2021 | -120.79% | -204.96% | 0.20x | 2.93x | $-85.88 Million |
| 2022 | 0.00% | -469.36% | 0.20x | 0.00x | $-91.20 Million |
| 2023 | -192.88% | -14.18% | 1.62x | 8.40x | $-8.55 Million |
Industry Comparison
This section compares Molecular Templates Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecular Templates Inc (MTEM) | $7.11 Million | 0.00% | 2.75x | $566.58 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |